ArticleMedicine2025
Significance of CD8+T cells related gene ITGB2 in prognosis and tumor microenvironment of small cell lung cancer.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CD8 + T cells could enhance response of antitumor immune in cancers. Therefore, we aimed to analyze the CD8 + T cells related genes in small cell lung cancer (SCLC) patients. The data of SCLC samples were collected from the Gene Expression Omnibus database. The hub genes were screened by weighted gene co-expression network analysis, protein-protein interaction network and survival analyses. Moreover, the relative proportions of the 22 immune cells in the samples were calculated using CIBERSORT software. The relationship between target gene and immunotherapy was analyzed in IMvigor210 cohort. We identified 10 genes (PTPRC, RPS27A, UBA52, CD8A, ITGB2, GNB2L1, TYROBP, CD86, TLR4, and FCGR3A) that were correlated with CD8 + T cells in SCLC. Among them, ITGB2 was positively correlated with CD8 + T cells in SCLC. ITGB2 was down-regulated in SCLC. SCLC patients with low ITGB2 expression exhibited a poor prognosis, and ITGB2 was an independent prognostic factor for survival rate of SCLC patients. The differentially expressed genes between ITGB2high and ITGB2low groups were significantly enriched in 143 signaling pathways. We also discovered that the ImmuneScore, StromalScore, and the expression of immune checkpoints (PD-1 (PDCD1), CTLA4, PDL-1 (CD274), TIGIT, IFNG, GZMA, TBX2, and IDO1) were significantly increased in ITGB2high group. Moreover, SCLC patients with high ITGB2 expression had lower tumor immune dysfunction and exclusion scores, and the proportion of urothelial cancer patients with complete response/partial response was observably decreased in ITGB2high group. Finally, we found that ITGB2 was correlated with IC50 of cancer drugs. In conclusion, SCLC patients with low ITGB2 expression exhibited worse prognosis. ITGB2 might be correlated with immunotherapy response of SCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.